Bio-Rad Laboratories, Inc., a global life sciences research and clinical diagnostic products organization has experienced significant trading activity. UBS Group AG, Brio Consultants LLC, Parnassus Investments LLC among others have purchased, sold, and adjusted positions in BIO stocks. Despite macroeconomic headwinds and rising expenses, its stocks continue to show some promise. Its stock has seen a loss of 14% in the past week painting a less than optimistic picture. A prominent trend is that multiple stakeholders like Norges Bank, First Pacific Advisors LP, etc are purchasing huge numbers of shares. The company has also received an upgrade to “Buy” status by StockNews.com. On the financial front, Q2 2024 Earnings and Q2 2025 earnings of the company have been commented on by Zacks Research. The company's Q1 2024 earnings surpassed estimates, but a decline is seen in the Q1 2023 sales. Additionally, the company overcame a 50% stock fall and achieved a stock increase in the last month, but a loss of 13% since the previous earnings report. Bio-Rad is also discussing a merger with Qiagen which could bring about significant changes.
Bio-Rad Laboratories Stocks News Analytics from Wed, 10 Jul 2019 07:00:00 GMT to Sun, 02 Jun 2024 16:02:28 GMT -
Rating 2
- Innovation -5
- Information 6
- Rumor 0
